We have followed the development and maturation of wearable continuous glucose monitors (CGM) solutions since 2014. In 2015, we wrote about the Animas Vibe insulin pump that connected wirelessly to a Dexcom G4 CGM. This past March we covered a new partnership between CGM developer Smart Meter and EHR software provider PointClickCare.
Dexcom is in the news again this year. The company announced additional clinical studies that support its CGM products’ benefit for people with Type 2 Diabetes (T2D). One of the studies reported that the Dexcom’s G6 mobile CGM can improve overall glycemic control for T2D patients who are treated with basal insulin. The mobile study included 175 adults with T2D who were randomly assigned to continuous glucose monitoring or traditional blood glucose meter monitoring. The clinical trial lasted for 8 months. According to the study published in the Journal of the American Medical Association, patients who use the Dexcom G6 had significant A1c reduction, increased time the proper blood glucose range, and a profound decrease in hyperglycemia. Also, more patients with the CGM reached their A1c goals compared to the glucose meter control group. Dexcom also published data on performance, features, and benefits of its latest generation CGM, the Dexcom G7.
The Dexcom mobile study confirms CGM benefits. This one more data point in support of the significant gains that can be produced by wearable health tech devices.
